Software Programmable I2C/SPI interface for APB

In questa tesi viene presentata una nuova architettura per un'interfaccia I2C/SPI per bus APB. Dopo un'analisi dei due protocolli viene descritta l'interfaccia creata, analizzando sia lo schema a blocchi che i segnali ed i registri coinvolti. Particolare attenzione viene fatta nel descrivere le procedure di test messe a punto per controllare la compatibilità dei segnali in uscita con i protocolli I2C o SPI. Dopo la verifica funzionale del sistema quest'ultimo è stato sintetizzato sia su FPGA che in tecnologia CMOS 0.18 micron, analizzando sia i valori di area occupata e di massima frequenza che la potenza dissipata e confrontando i valori ottenuti dai simulatori con quelli di altre IP commerciali disponibili in rete. Non esistendo un'interfaccia I2C/SPI in commercio il confronto è stato effetuato tra i singoli sottomoduli (relativi all'I2C o all'SPI). I risultati ottenuti dimostrano come l'interfaccia presentata abbia performance analoghe o migliori di altre strutture presenti in commercio

Magnetic Flux Leakage Method: Large-Scale Approximation

We consider the application of the magnetic flux leakage (MFL) method to the detection of defects in ferromagnetic (steel) tubulars. The problem setup corresponds to the cases where the distance from the casing and the point where the magnetic field is measured is small compared to the curvature radius of the undamaged casing and the scale of inhomogeneity of the magnetic field in the defect-free case. Mathematically this corresponds to the planar ferromagnetic layer in a uniform magnetic field oriented along this layer. Defects in the layer surface result in a strong deformation of the magnetic field, which provides opportunities for the reconstruction of the surface profile from measurements of the magnetic field. We deal with large-scale defects whose depth is small compared to their longitudinal sizes---these being typical of corrosive damage. Within the framework of large-scale approximation, analytical relations between the casing thickness profile and the measured magnetic field can be derived.Comment: 12 pages, 3 figure

Noise-Produced Patterns in Images Constructed from Magnetic Flux Leakage Data

Magnetic flux leakage measurements help identify the position, size and shape of corrosion-related defects in steel casings used to protect boreholes drilled into oil and gas reservoirs. Images constructed from magnetic flux leakage data contain patterns related to noise inherent in the method. We investigate the patterns and their scaling properties for the case of delta-correlated input noise, and consider the implications for the method's ability to resolve defects. The analytical evaluation of the noise-produced patterns is made possible by model reduction facilitated by large-scale approximation. With appropriate modification, the approach can be employed to analyze noise-produced patterns in other situations where the data of interest are not measured directly, but are related to the measured data by a complex linear transform involving integrations with respect to spatial coordinates.Comment: 11 pages, 2 figure

Road and bridge construction across gypsum karst in England

Gypsum karst problems in the Permian and Triassic sequences of England have caused difficult conditions for bridge and road construction. In Northern England, the Ripon Bypass crosses Permian strata affected by active gypsum karst and severe subsidence problems. Here, the initial borehole site investigation for the road was supplemented by resistivity tomography studies. The roadway was reinforced with two layers of tensile membrane material within the earth embankment. This will prevent dangerous catastrophic collapse, but will allow sagging to show where problems exist. The River Ure Bridge was constructed across an area of subsidence pipes filled with alluvial deposits. It was built with extra strength, larger than normal foundations. If one pier fails, the bridge is designed for adjacent arches to span the gap without collapse. The bridge piers are also fitted with electronic load monitoring to warn of failure. In the Midlands area of England, road construction over Triassic gypsum has required a phase of ground improvement on the Derby Southern Bypass. Here, the gypsum caps a hill where it was formerly mined; it dips through a karstic dissolution zone into an area of complete dissolution and collapse. The road and an associated flyover were built across these ground conditions. A major grouting program before the earthworks began treated the cavities in the mine workings and the cavernous margin of the gypsum mass. Within the karstic dissolution zone, gypsum blocks and cavities along the route were identified by conductivity and resistivity geophysical surveys, excavated and backfilled. In the areas of complete dissolution and collapse, the road foundation was strengthened with vibrated stone columns and a reinforced concrete road deck was used

Shielding effectiveness of textile woven fabric with conductive weft in microwave frequency range

The article examines the shielding effectiveness of fabrics with conductive fibres in the microwave frequency range. Because of the limited size of the samples and high frequency range, the methods presented in literature could not be applied in this research. The method proposed, using a special measurement setup, demonstrated practicality for smaller textile samples. The results showed an angular dependence of shielding effectiveness, suggesting the need for perpendicular orientation of conductive fibres in fabrics to maximize shielding. This research provides knowledge on tailored solutions to mitigate electromagnetic interference in modern electronic technologies

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: Sotrovimab is a neutralising monoclonal antibody targeting the SARS-CoV-2 spike protein. We aimed to evaluate the efficacy and safety of sotrovimab in the RECOVERY trial, an investigator-initiated, individually randomised, controlled, open-label, adaptive platform trial testing treatments for patients admitted to hospital with COVID-19. Methods: Patients admitted with COVID-19 pneumonia to 107 UK hospitals were randomly assigned (1:1) to either usual care alone or usual care plus a single 1 g infusion of sotrovimab, using web-based unstratified randomisation. Participants were eligible if they were aged at least 18 years, or aged 12–17 years if weighing at least 40kg, and had confirmed COVID-19 pneumonia with no medical history that would put them at significant risk if they participated in the trial. Participants were retrospectively categorised as having a high antigen level if baseline serum SARS-CoV-2 nucleocapsid antigen was above the median concentration (the prespecified primary efficacy population), otherwise they were categorised as having a low antigen level. The primary outcome was 28-day mortality assessed by intention to treat. Safety outcomes were assessed among all participants, regardless of antigen level. Recruitment closed on March 31, 2024, when funding ended. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: From Jan 4, 2022, to March 19, 2024, 1723 patients were enrolled in the RECOVERY sotrovimab comparison. Of these, 828 (48%) were assigned to usual care plus sotrovimab and 895 (52%) were assigned to usual care only. Mean patient age was 70·7 years (SD 14·8) and 1033 (60%) were male. 720 (42%) patients were classified as having a high antigen level, 717 (42%) as having a low antigen level, and 286 (17%) had unknown antigen status. 1389 (81%) patients were vaccinated, 1179 (82%) of 1438 patients with known serostatus had anti-spike antibodies at randomisation, and 1021 (>99%) of 1026 patients with sequenced samples were infected with omicron variants. Among patients with a high antigen level, 82 (23%) of 355 assigned to sotrovimab versus 106 (29%) of 365 assigned usual care died within 28 days (rate ratio 0·75, 95% CI 0·56–0·99; p=0·046). In an analysis of all randomly assigned patients (regardless of antigen status), 177 (21%) of 828 patients assigned to sotrovimab versus 201 (22%) of 895 assigned to usual care died within 28 days (0·95, 0·77–1·16; p=0·60). Infusion reactions were recorded in 12 (2%) of 781 patients receiving sotrovimab. We found no difference between groups in any other safety outcome. Interpretation: In patients admitted to hospital with COVID-19 pneumonia, sotrovimab was associated with reduced mortality in the primary analysis population who had a high serum SARS-CoV-2 antigen concentration at baseline, but not in the overall population. Treatment options for patients admitted to hospital are limited, and mortality in those receiving current standard of care was high. The emergence of high-level resistance to sotrovimab among subsequent SARS-CoV-2 variants restricts its current usefulness, but these results indicate that targeted neutralising antibody therapy could potentially still benefit some patients admitted to hospital who are at high risk of death in an era of widespread vaccination and omicron infection. Funding: UK Research and Innovation (Medical Research Council) and National Institute for Health and Care Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Family Business e scelte finanziarie: un'analisi empirica

In questo elaborato si esplora il legame tra la proprietà familiare e il quoziente di indebitamento. In aggiunta, si osserva come questa relazione cambia in presenza di un manager appartenente alla famiglia proprietaria e come la proprietà familiare incide nella relazione tra indebitamento finanziario e rischiosità di impresa. Si analizza la proporzione di debito finanziario applicando un modello pooled OLS su un database comprensivo di 1072 PMI italiane nel periodo 2012-2019. I risultati suggeriscono che le family business sono in media più indebitate delle imprese non familiari. D’altro canto, il coinvolgimento manageriale non sembra un elemento significativo nella spiegazione del livello di indebitamento e le imprese con proprietà familiare e rischio elevato risultano essere più avverse al ricorso al capitale di debito. Le analisi di robustezza, che confermano i risultati ottenuti dall’analisi principale, includono modelli di regressione frazionale e definizioni alternative di impresa familiare e degli indicatori di indebitamento. In this thesis we investigate the hypothesis that family ownership and management reduce agency problems related to financial leverage. In addition, we examine the influence of family ownership on firm’s financial risk. We use an unbalanced data panel comprehensive of 1072 Italian SMEs over the 2012-2019 and perform basic pooled regression and random fractional regression for panel data. Our results shows that family businesses are more indebted than no-family business. However family management does not seem significant in influencing leverage ratios. Furthermore, family firms with higher risk seem more averse to issue debt